Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 8/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.45 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.41 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.41 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38111 | 1.00 | GRIK1 (0.47) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| SCHEMBL2024581 | 1.00 | GRIK1 (0.47) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| SCHEMBL28097905 | 0.98 | GRIK1 (0.46) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| Hydrochloric Acid SCHEMBL6361420 | 0.98 | GRIK1 (0.46) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| Methane SCHEMBL15302692 | 0.98 | GRIK1 (0.46) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| SCHEMBL28097904 | 0.98 | GRIK1 (0.46) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| Methane SCHEMBL15302681 | 0.98 | GRIK1 (0.46) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| Water SCHEMBL27830506 | 0.98 | GRIK1 (0.46) | GRIK1SLC7A5GRIK2GRM1GRM2 | |
| SCHEMBL8149690 | 0.87 | SLC7A5 (0.47) | GRIK1SLC7A5GRIK2GRIA4GRIK3 | |
| SCHEMBL3600281 | 0.87 | SLC7A5 (0.47) | GRIK1SLC7A5GRIK2GRIA4GRIK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119350450-A | Water-based synthesis method of mu-conotoxin KIIIA with instant wrinkle removal effect | 润辉生物技术（威海）有限公司 | 2025-01-24 | — | — | CN | claimed |
| CN-117777248-A | Water-based solid phase synthesis method of multi-receptor agonist polypeptide Retatrutide | 润辉生物技术（威海）有限公司 | 2024-03-29 | — | — | CN | claimed |
| CN-117024316-A | 2, 4-binitro-6-phenyl-phenylthio protecting group and polypeptide synthesis method thereof | 南开大学 | 2023-11-10 | — | — | CN | claimed |
| CN-107473978-B | Curcumin derivative and preparation method and application thereof | GUANGDONG UNIVERSITY OF TECHNOLOGY (CN) | 2019-12-10 | — | — | CN | claimed |
| CN-106045883-B | A kind of preparation method of aspartic acid -1- tert-butyl ester derivatives | 成都郑源生化科技有限公司 | 2018-06-22 | — | — | CN | claimed |
| CN-1450999-A | Novel piperazine derivatives | PFIZER PROD INC (US) | 2003-10-22 | — | — | CN | claimed |
| WO-2026099867-A1 | SUSTAINABLE ANTIFREEZE COATINGS BY PEPTIDE SELF-ASSEMBLY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2026-05-15 | — | — | WO | disclosed |
| US-12605451-B2 | Targeted plasma protein degradation | NOVARTIS AG (CH) | 2026-04-21 | — | — | US | disclosed |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-12-04 | — | — | US | disclosed |
| CN-120202010-A | Ligand-oligonucleotide conjugates and linkers for use therewith | 上海京新生物医药有限公司 | 2025-06-24 | — | — | CN | disclosed |
| EP-4504732-A2 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | University of Connecticut (US) | 2025-02-12 | — | — | EP | disclosed |
| US-12209144-B2 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2025-01-28 | — | — | US | disclosed |
| CN-119350450-A | Water-based synthesis method of mu-conotoxin KIIIA with instant wrinkle removal effect | 润辉生物技术（威海）有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-1111630-A | Adhesion receptor antagonists | MERCK PATENT GMBH (DE) | 1995-11-15 | — | — | CN | disclosed |
| EP-0301751-B1 | PYRIDINIUM DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1993-03-10 | — | — | EP | disclosed |
| US-4962113-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD (JP) | 1990-10-09 | — | — | US | disclosed |
| EP-0301751-A1 | Pyridinium derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1989-02-01 | — | — | EP | disclosed |
| EP-0082712-B1 | 2-PHENYLIMIDAZO(2,1-B)BENZOTHIAZOLE COMPOUNDS, SALTS THEREOF, PROCESS FOR PRODUCING THEM, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1987-06-16 | — | — | EP | disclosed |
| US-4464384-A | SUPPRESSANTS OF IMMUNE RESPONSE | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1984-08-07 | — | — | US | disclosed |
| EP-0082712-A2 | 2-Phenylimidazo(2,1-b)benzothiazole compounds, salts thereof, process for producing them, and pharmaceutical compositions containing them | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1983-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | EPCAM, CD47, JAK2 | GRIK1 3939/4885SLC7A5 1405/4885GRIK2 4289/4885 |
| US-12605451-B2 | Targeted plasma protein degradation | M6PR, ASGR1, IGF2R | GRIK1 4488/4885SLC7A5 445/4885GRIK2 4417/4885 |
| US-12209144-B2 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | GRIK1 3042/4885SLC7A5 2930/4885GRIK2 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.